Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous ...

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.

Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to ...

Eisai (ESAIY) and Biogen (BIIB) announced that Eisai has filed a new drug application for Leqembi seeking approval for a subcutaneous formulation ...

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in ...

Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant ...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new ...